Greenwich LifeSciences, Inc. (GLSI)

Market Cap	168.96M
Revenue (ttm)	n/a
Net Income (ttm)	-8.89M
Shares Out	12.88M
EPS (ttm)	-0.69
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	27,889
Open	12.57
Previous Close	12.34
Day's Range	12.30 - 13.29
52-Week Range	7.58 - 21.44
Beta	3.19
Analysts	Strong Buy
Price Target	36.00 (+174.39%)
Earnings Date	Apr 15, 2024

About GLSI

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is h...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Sep 25, 2020
• Employees: 3
• Stock Exchange: NASDAQ
• Ticker Symbol: GLSI

Analyst Forecast

According to one analyst, the rating for GLSI stock is "Strong Buy" and the 12-month stock price forecast is $36.0.

Price Target

$36.0

(174.39% upside)

Analyst Consensus: Strong Buy